)
Edge14 Nov 2025
Ball: The King of Cans
From a 19th-century glass-jar legacy to a global plant network, Ball is now a pure-play aluminum can partner to the world's biggest beverage brands.
Ventyx Biosciences (VTYX) investor relations material
Ventyx Biosciences Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Focused on developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, with clinical-stage candidates VTX2735, VTX3232, tamuzimod, and VTX958 in various trials and stages of development.
Achieved key milestones with positive Phase 2a data for VTX3232 in Parkinson's disease and Phase 2 data in obesity/cardiovascular risk factors.
VTX3232 demonstrated significant reductions in inflammatory biomarkers, supporting its potential as a next-generation oral anti-inflammatory therapy.
Net loss for Q3 2025 was $22.8 million, and $77.3 million for the nine months ended September 30, 2025, reflecting ongoing R&D investment and no product revenue.
Raised $95.0 million in a March 2024 private placement and $26.6 million in a September 2024 Series A preferred stock private placement.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $192.6 million as of September 30, 2025, expected to fund operations into at least H2 2026.
Q3 2025 net loss was $22.8 million, improved from $35.2 million in Q3 2024; nine-month net loss was $77.3 million, improved from $105.8 million in the prior year period.
Operating expenses for Q3 2025 were $24.9 million, down from $38.6 million in Q3 2024, driven by lower R&D and G&A costs.
R&D expenses were $17.7 million and G&A expenses were $7.2 million for Q3 2025.
Basic and diluted net loss per share was $0.32 for Q3 2025 and $1.08 for the nine months ended September 30, 2025.
Outlook and guidance
Existing cash, cash equivalents, and marketable securities expected to fund obligations for at least 12 months from the report date and into at least the second half of 2026.
Anticipates increased R&D costs for VTX2735 and decreased costs for tamuzimod and VTX958 as trials close out.
Topline data from the Phase 2 study of VTX2735 in recurrent pericarditis expected in Q4 2025.
Exploring partnership opportunities for tamuzimod in ulcerative colitis and VTX958 in Crohn's disease.
No product revenue expected for several years; future funding needs anticipated for continued development and potential commercialization.
VTX3232: Prioritize CV or neuro indications?
Rationale for IBD portfolio partnership strategy
Is current R&D spend sustainable for pipeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ventyx Biosciences earnings date
Q4 202526 Feb, 2026
Next Ventyx Biosciences earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel oral therapies designed to treat patients with autoimmune and inflammatory disorders. The company's approach involves selectively modulating key immune targets to create differentiated medicines. Ventyx Biosciences is working on several promising drug candidates, including a selective allosteric tyrosine kinase type 2 inhibitor and a sphingosine 1 phosphate receptor modulator, which are in various stages of clinical trials targeting conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Additionally, they are developing inhibitors targeting the NLRP3 inflammasome. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage